© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
RxSight, Inc. (RXST) stock declined over -1.15%, trading at $5.14 on NASDAQ, down from the previous close of $5.20. The stock opened at $5.10, fluctuating between $5.08 and $5.22 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 21, 2026 | 5.21 | 5.34 | 5.05 | 5.14 | 627.65K |
| Sep 18, 2026 | 5.25 | 5.36 | 5.17 | 5.20 | 1.08M |
| Sep 17, 2026 | 5.58 | 5.58 | 5.17 | 5.32 | 1.01M |
| Sep 16, 2026 | 5.56 | 5.58 | 5.31 | 5.40 | 802.95K |
| Sep 15, 2026 | 6.05 | 6.05 | 5.60 | 5.62 | 679.24K |
| Sep 14, 2026 | 6.02 | 6.21 | 5.96 | 6.11 | 632.07K |
| Sep 11, 2026 | 6.00 | 6.03 | 5.78 | 6.02 | 450.63K |
| Sep 10, 2026 | 6.26 | 6.33 | 5.89 | 5.96 | 666.41K |
| Sep 09, 2026 | 6.41 | 6.66 | 6.27 | 6.33 | 1.21M |
| Sep 08, 2026 | 6.28 | 6.47 | 6.05 | 6.45 | 733.05K |
| Sep 04, 2026 | 6.47 | 6.63 | 6.34 | 6.38 | 560.33K |
| Sep 03, 2026 | 7.11 | 7.11 | 6.48 | 6.54 | 605.35K |
| Sep 02, 2026 | 6.96 | 7.35 | 6.91 | 7.03 | 778.87K |
| Sep 01, 2026 | 7.28 | 7.44 | 6.96 | 6.99 | 988.89K |
| Aug 31, 2026 | 7.05 | 7.36 | 7.00 | 7.33 | 1.29M |
| Aug 28, 2026 | 6.59 | 7.06 | 6.55 | 7.05 | 663.39K |
| Aug 27, 2026 | 6.36 | 6.69 | 6.27 | 6.61 | 580.12K |
| Aug 26, 2026 | 6.36 | 6.61 | 6.19 | 6.38 | 1.72M |
| Aug 25, 2026 | 6.23 | 6.41 | 6.14 | 6.40 | 366.35K |
| Aug 24, 2026 | 6.26 | 6.55 | 6.18 | 6.26 | 480.56K |
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
| Employees | 461 |
| Beta | 1.16 |
| Sales or Revenue | $89.08M |
| 5Y Sales Change% | 30.867% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |